Microport Cardioflow Medtech

Microport Cardioflow Medtech EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Microport Cardioflow Medtech (2160.HK) as of Nov 13, 2026 is -9.94. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -9.53 — a change of 4.31% (lower).

EV/FCF

-9.94

YoY

4.31%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Microport Cardioflow Medtech is 2024 -9.94 . EV/FCF (Enterprise Value to Free Cash Flow) of Microport Cardioflow Medtech was 2023 -9.53 . It decreases by 4.31% lower compared to the previous year.

The Microport Cardioflow Medtech EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-28.97 CNY
Jan 1, 2019
-20.34 CNY
Jan 1, 2020
-20.05 CNY
Jan 1, 2021
-6.25 CNY
Jan 1, 2022
-8.57 CNY
Jan 1, 2023
-9.53 CNY
Jan 1, 2024
-9.94 CNY
The Microport Cardioflow Medtech EV/FCF history
YEAREV/FCFYoY
-9.94+4.31%
-9.53+11.12%
-8.57+37.15%
-6.25-68.83%
-20.05-1.42%
-20.34-29.78%
-28.97—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Microport Cardioflow Medtech Stock analysis

What does Microport Cardioflow Medtech do? MicroPort CardioFlow Medtech Corp. develops and commercializes transcatheter and surgical solutions for valvular heart diseases, primarily focusing on the domestic market. The company's main products are the first-generation TAVI product VitaFlow and the second-generation TAVI product VitaFlow II, which are used for transcatheter aortic heart valve implantation. These products are sold to healthcare providers and hospitals within China, where the company operates under its holding company structure. The firm generates revenue through the sale of its medical devices, specifically the VitaFlow and VitaFlow II systems, targeting hospitals and medical institutions that require advanced cardiac solutions. As a domestic-focused entity, MicroPort CardioFlow's business model relies on the commercialization of its TAVI products within China's healthcare sector, with no mention of international markets or additional product lines beyond the two TAVI systems. Microport Cardioflow Medtech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Microport Cardioflow Medtech stock

EV/FCF (Enterprise Value to Free Cash Flow) of Microport Cardioflow Medtech is -9.94 in 2024.

EV/FCF (Enterprise Value to Free Cash Flow) of Microport Cardioflow Medtech changed from -9.53 to -9.94, representing a 4.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Microport Cardioflow Medtech since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Microport Cardioflow Medtech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Microport Cardioflow Medtech

All Key Metrics — Microport Cardioflow Medtech